Oppenheimer Asset Management’s Castle Biosciences CSTL Stock Holding History

Oppenheimer Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,989	Closed	-$223K	–	1172
2022 Q1	$223K	Buy	+4,989	New	+$206K	﹤0.01%	1102
2021 Q4	–	Sell	-4,374	Closed	-$291K	–	1236
2021 Q3	$291K	Sell	4,374 -80	-2%	-$5.63K	﹤0.01%	1061
2021 Q2	$326K	Buy	4,454 +79	+2%	+$5.22K	﹤0.01%	1046
2021 Q1	$300K	Buy	+4,375	New	+$329K	﹤0.01%	1031

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Oppenheimer Asset Management's CSTL Position: Q2 2022 in Review

Oppenheimer Asset Management sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 4,989 shares — an estimated $223K sold.

Oppenheimer Asset Management first reported a position in CSTL in Q1 2021 and held it in 4 quarters. The position peaked at $326K in Q2 2021. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

Oppenheimer Asset Management reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
Oppenheimer Asset Management sold 4,989 Castle Biosciences shares in Q2 2022, an estimated $223K.
Oppenheimer Asset Management first reported a position in Castle Biosciences in Q1 2021 and held it in 4 quarters.
Oppenheimer Asset Management's Castle Biosciences position peaked at $326K in Q2 2021.
146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Oppenheimer Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.